Chime Financial stock initiated with buy rating at Texas Capital

Texas Capital Securities initiated Chime Financial with a buy rating and a $28 price target, implying 34% upside from the $22.26 share price. The firm highlighted Chime’s 9.5 million consumers, 88% gross margin, and projected 20% revenue CAGR from 2025 to 2028 with a 22% EBITDA margin in 2028. Recent results showed Q4 2025 EPS of -$0.12 and full-year revenue of about $2.2 billion, up 31% year over year, while other brokers remain bullish with $30 targets.

Analysis

The market is treating this as a straightforward growth re-rate, but the more important signal is that Chime is approaching the point where incremental user growth can start compounding operating leverage faster than investors expect. With a largely fee-based model and high gross margin, even modest improvements in transaction frequency or checking adoption can push EBITDA trajectory meaningfully higher than headline user adds imply. That makes the stock less about near-term EPS and more about whether management can sustain monetization per active user while keeping acquisition costs from inflating.

The competitive read-through is that public-market fintech multiples may stay bid, but the real winner is whichever platform can convert brand awareness into primary-bank behavior. That favors Chime relative to neobanks that are still dependent on episodic engagement, while pressuring incumbent banks on lower-balance deposit relationships where interchange and payments are the real profit pool. If Chime’s user adds slow, the market will likely punish the stock quickly because the valuation is still anchored to a long-duration growth narrative rather than current earnings power.

The main risk is not valuation in isolation; it is a second-order slowdown in consumer activity that hits interchange intensity before revenue growth visibly decelerates. That would show up first over the next 1-2 quarters in weaker transaction frequency or softer net new checking conversions, which would compress the path to the 2028 margin story. Conversely, any sign of accelerating credit product adoption could force upward revisions because the market is underestimating how quickly ancillary products can expand lifetime value if underwriting stays tight.

Consensus looks mildly too optimistic on the durability of 20% CAGR, but not by enough to justify fighting the tape aggressively. The cleaner setup is to express bullishness through relative value rather than outright directional exposure, because the stock can continue to work even if growth moderates modestly, as long as the path to EBITDA remains intact.

Key Decisions for Investors

• Long CHYM on pullbacks below the post-initiation consensus range, with a 3-6 month horizon; target a re-rating toward peer EV/EBITDA if user adds and checking engagement stay intact. Use a tight risk limit if quarterly net adds fall materially below management/Street expectations.
• Pair trade: long CHYM / short a lower-momentum public fintech basket over 2-4 quarters. The thesis is that market share gains and operating leverage should separate the strongest consumer fintech platform from names with weaker engagement, while limiting factor exposure to the fintech multiple regime.
• Buy CHYM call spreads for the next 2 earnings cycles rather than common stock if implied volatility is elevated. This captures upside from continued growth revisions while defining risk if interchange trends soften or the market discounts the 2028 margin story.
• Watch for any confirmation of credit product traction; if visible in commentary or KPIs, add to CHYM on strength. The market is likely underpricing optionality from higher-LTV products, which can expand valuation faster than the base-case payments model alone.
• Avoid chasing MS on this headline as a pure proxy trade; the cleaner alpha is in CHYM relative to other fintechs, not the analyst sponsor. The broad read-through is supportive for sentiment, but the direct economic impact is concentrated in the operating model, not the broker.